State Street reports 17.45M Iovance shares (4.2%)
State Street Corporation reports beneficial ownership of 17,448,108 shares of Iovance Biotherapeutics common stock, representing 4.2% as of 03/31/2026.
Rhea-AI Filing Summary
State Street Corporation reports beneficial ownership of 17,448,108 shares of Iovance Biotherapeutics common stock, representing 4.2% as of 03/31/2026.
The filing shows shared voting power of 16,532,266 shares and shared dispositive power over 17,448,108 shares. The Schedule 13G lists several State Street advisory subsidiaries as the reporting entities. The signature block is dated 05/12/2026.
Positive
- None.
Negative
- None.
Insights
State Street discloses a 4.2% passive holding in Iovance as of 03/31/2026.
The Schedule 13G identifies 17,448,108 shares beneficially owned and shows shared voting power of 16,532,266. Multiple State Street advisory subsidiaries are listed as the reporting entities, indicating holdings managed across funds.
Impact is routine: the filing documents passive ownership and voting/dispositive allocations. Subsequent filings would show any change in position or conversion to an active filing status.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned financial
Advisory subsidiaries other
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does State Street report in IOVA?
Does the filing show voting or dispositive power for State Street?
Which State Street entities are named on the 13G for IOVA?
What reporting dates are shown in the IOVANCE 13G?
Does this Schedule 13G indicate active control or activism?
AI-generated analysis. How Rhea-AI works. Not financial advice.